# A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

> **NCT02035605** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 51 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** ALN-AT3SC
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02035605
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-20
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-07-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035605, "A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02035605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*